Results 101 to 110 of about 5,563 (240)

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo

, 2023
Neutralizing antibodies exert a potent inhibitory effect on viral entry; however, they are less effective in therapeutic models than in prophylactic models, presumably because of their limited efficacy in eliminating virus-producing cells via Fc-mediated
Qiang Dai, Fanlin Li, Xinyue Qi, Lu Lu, Shan Su, Huihui Zhang, Xiaoqing Zhang, Shibo Jiang, Xuanming Yang, Xin Wang, Haiyong Wang, Min Li, Hao Lin, Wei Xu, Jie Liang, Yanqin Xu, Youhua Xie, Ping Han, Lilv Fan, Wanting Wang   +19 more
core   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics

Pharmacology & Therapeutics, 2018
Harnessing the power of the human immune system to treat cancer is the essence of immunotherapy. Monoclonal antibodies engage the innate immune system to destroy targeted cells. For the last 30years, antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity have been the main mechanisms of anti-tumor action of unconjugated ...
Z, Wu, N V, Cheung
openaire   +3 more sources

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. [PDF]

, 2015
The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic leukemia (ALL). However, about half of relapsed/refractory patients do not respond to therapy.
Tischer, J., Köhnke, T., Krupka, C., Tischer, Johanna, Köhnke, Thomas, Krupka, Christina, Subklewe, Marion, Subklewe, M., Knösel, T., Knösel, Thomas   +9 more
core   +1 more source

Recent Advances in Photocatalyst‐Driven Protein Labeling and Proximity Mapping

The Chemical Record, EarlyView.
Photocatalyst‐driven protein labeling and proximity mapping have rapidly advanced as powerful strategies for spatiotemporal control in complex biological environments. This review integrates recent developments across single‐electron transfer and energy transfer‐based mechanisms and highlights how catalyst design, reactive intermediates, and diffusion ...
Shinichi Sato, Kazuki Miura, Juki Nakao, Hiroyuki Nakamura   +3 more
wiley   +1 more source

Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies

Cancers
Objectives: Reduced expression of adhesion molecules in tumor vasculature can limit infiltration of effector T cells. To improve T cell adhesion to tumor endothelial cell (EC) antigens and enhance transendothelial migration, we developed bispecific, T-cell engaging antibodies (bsAb) that activate T cells after cross-linking with EC cell surface ...
Márcia Gonçalves, Karsten M. Warwas, Marten Meyer, Reinhard Schwartz-Albiez, Nadja Bulbuc, Inka Zörnig, Dirk Jäger, Frank Momburg   +7 more
openaire   +2 more sources

Enhancing oncolytic virotherapy of glioblastoma by targeting innate immune ligands with a bispecific T cell engager

, 2023
Glioblastoma (GBM) is a highly aggressive brain tumour in adults, often becoming resistant towards conventional therapy of radiotherapy and temozolomide (TMZ) chemotherapy.
Baugh, Richard
core   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

Bispecific Protein Engager-Armed T Cells (BATs): Next-Generation Platforms for Precision Cancer Immunotherapy

Siriraj Medical Journal
Chimeric antigen receptor (CAR) T-cell therapy and CD3-directed bispecific T-cell engagers (BiTEs) have transformed cancer immunotherapy, particularly for relapsed or refractory hematologic malignancies.
Pa-thai Yenchitsomanus
doaj   +1 more source

Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma [PDF]

Advanced cholangiocarcinoma (CCA) presents a clinical challenge due to limited treatment options, necessitating exploration of innovative therapeutic approaches.
Maher, John; id_orcid
core   +1 more source